- Lobbying
- sarepta AND therapeutics
Lobbying Arrangements Results for 'Sarepta Therapeutics'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Issues related to approval of new treatments for rare diseases. |
Sarepta Therapeutics
|
Squire Patton Boggs | |||
Details FY 2023 Labor HHS appropriations bill; Funding for the CDC; Newborn Screening program |
Sarepta Therapeutics, Inc.
|
Cornerstone Government Affairs, Inc. | |||
Details Issues related to patient access to treatments Issues related to rare diseases Issues related to newborn screening Issues related to scientific innovation in healthcare Public Law 117-169, Inflatio... |
Sarepta Therapeutics, Inc.
|
in-house lobbying | |||
Details Rare disease related policies |
Sarepta Therapeutics, Inc.
Develop new therapies that make a meaningful difference in the lives of patients |
Waller Lansden Dortch & Davis LLP | |||
Details Increased funding for the Newborn Screening Quality Assurance Program at the Centers for Disease Control and Prevention in the FY 2022 Labor-HHS Appropriations Bill Issues related to funding for th... |
Cornerstone Government Affairs (on behalf of RUSP Coalition)
|
Avenue Solutions | |||
Details Issues related to Medicare and Medicaid reimbursement; Issues related to rare diseases. Issues related to Medicare and Medicaid reimbursement; Issues related to rare diseases; Issues related to new... |
Sarepta Therapeutics
|
Forbes-Tate | |||
Details Federal budget issues IRA implementation, innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program... |
Sarepta Therapeutics
|
TARPLIN, DOWNS & YOUNG, LLC |